PTO/SB/08A (07-05) Approved for use through 07/31/2005. OMB 0651-0031 U.S. Patent end Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of information unless it contains a valid OMB control numb Complete if Known

Substitute for form 1449/PTO

of 3

INFORMATION DISCLOSURE ATEMENT BY APPLICANT (Use as many sheets as necessary)

Sheet

Application Number 10/562.951 Filing Date December 23, 2005 First Named Inventor Brian Anderton, et al. Art Unit Not vet assigned **Examiner Name** Not yet assigned Attomey Docket Number 0380-P03923US0

		_	U. S. PATENT	DOCUMENTS	/
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

		/	FOREIGN PATENT DOCU	MENTS \		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevent Passages	П
			MM-DD-YYYY		Or Relevant Figures Appear	Te
Examiner	T-			Date	$\overline{}$	_

"EXAMINER: Initial If derence considered, whether or not clation is in conformance with MPEP 609. Traw line through clation if no in conformance and not considered, include/cony of this form with next communication to applicant. "Applicant's unique clation designation number (options)." See Kinds Codes of USPTO Patent Usermines at <u>www.usprogroup or or MPEP 9010-00.</u>" Enter Office the Issued the document, by the two-clate code (WIPO Statement 37.3." For Japanese paraly documents, he indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind'off document by the supporting should as indicated on the document under WIPO Standard St. 15 of possible." Applicant is to place on check mark her sign language

oglion of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file lead by the ro process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any compone amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pa Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND O: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTC/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Petent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons an Substitute for form 1449/PTO	e required to respond to e collection of information unless it contains a valid CMB control number. Complete if Known		
	Application Number	10/562,951	
INFORMATION DISCLOSURE	Filing Date	December 23, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Brian Anderton, et al.	
(Use as many sheets as necessary)	Art Unit	Not yet assigned	
(ose as many should as necessary)	Examiner Name	Not yet assigned	
Sheel 2 of 3	Attorney Docket Number	0380-P03923US0	

	L on	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		GHOSHAL, N. et al., "A New Molecular Link between the Fibrillar and Granulovacuolar Lesions of Alzheimer's Disease," American Journal of Pathology, 155(4):1163-1172, (1999)	
		HANGER, D. et al., "New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament-Tau) from," Journal of Neurochemistry, 71:2465-2476, (1998)	
		LAMBERT, M. et al., "Diffusible, nonfibrillar ligands derived from AB1-42 are potent central nervous system neurotoxins," Proc. Natl. Acad. Sci., 95:6448-6453, (1998)	
		LEE, V. et al., "Neurodegenerative Tauopathies," Annu. Rev. Neurosci., 24:1121-1159, (2001)	
		MULOT, S. et al., "PHF-tau from ALIzheimer's brain comprises four species on SDS-PAGE which can be," Federation of European Biochemical Societies, 349:359-364, (1994)	
		SHIRAZI, S. et al., "The protein tyrosine kinase, fyn, in Alzheimer's disease pathology," Neuro Report, 4:435-437, (1993)	
		SINGH, T. et al., "Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by," Federation of European Biochemical Societies, 358:4-8, (1995)	
		SINGH, T. et al., "Rapid Alzheimer-like phosphorylation of tau by the synergistic actions," Federation of European Biochemical Societies, 358:267-272, (1995)	
		WILLIAMSON, R. et al., "Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in," The Journal of Neuroscience, 22(1):10-20 (2002)	
		GOEDERT, M. et al., "Cloning and sequencing of the cDNA encoding an isoform of microlubule-associated protein tau containing four," The EMBO Journal, 8(2):393-399 (1989)	

Signature		Considered	
*EXAMINER: In	nitial if reference considered, whether or not citation is in conformance with MPEP 609	Draw line through c	itation if not in conformance and not

Examiner

Date

considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (coloron), 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain to benefit by the public his to file (and by the USPTO to process) an applicant. Confidentiality is governed by 3.0 U.S. (1.22 and 7.75 R 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Three will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Dox 1194, Mexandis, Own 2013-11450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	e required to respond to e collection of information unless it contains a valid OMB control number. Complete if Known		
	Application Number	10/562,951	
INFORMATION DISCLOSURE	Filing Date	December 23, 2005	
STATEMENT BY APPLICANT	First Named Inventor	Brian Anderton, et al.	
(Use as many sheets es necessary)	Art Unit	Not yet assigned	
(Use as many sheets as necessary)	Examiner Name	Not yet assigned	
Sheet 3 of 3	Attorney Docket Number	0380-P03923US0	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOEDERT, M. et al., "Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and," The EMBO Journal, 9(13):4225-4230, (1990)	
		GRAVES, P. et al., "Molecular Cloning, Expression, and Characterization of a 49- Kilodalton Casein," The Journal of Biological Chemistry, 268(9):6394-6401, (1993)	
		GOEDERT, M. et al., "Multiple Isoforms of Human Microtubule-Associated Protein Tau: Sequences and Localization in Neurofibrillary Tangles of," Neuron., 3:519-526, (1989)	
		SCALES, T. et al., "Tyrosine Phosphorylation of Specific Sites on Tau by SRC Family Kinases," Neurobiol. Aging, 23:S500-S501, (2002)	

PEVALUNED. I	bid if of one or other than the state of the	0 D F H A	9 41 - 241
Signature	/David Steadman/	Considered	09/12/2008

Evaminer

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

is in conformance with MPEP 609. Draw line through citation if not in co *EXAMINER: Initial if reference considered, whether or not citation is in conficence. Include copy of this form with next communication to applicant.

considered. Include copy of the form with nest communication to appeared.

Applicant's runger calcitant designation mustbe (collocal). Applicant is not place a check mark here if English language Translation is attached.

Applicant's runger calcitant designation number (collocal). Applicant is not place and not creating a benefit by the public which is to list (and by the USPTO to process an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.4.

The process of th Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.